Online inquiry

IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10835MR)

This product GTTS-WQ10835MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets FOLR1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_000802.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2348
UniProt ID P15328
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10835MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5235MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CB 2679d
GTTS-WQ2205MR IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ALT-803
GTTS-WQ5607MR IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CDP791
GTTS-WQ13132MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-04360365
GTTS-WQ9672MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64052781
GTTS-WQ11055MR IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MCLA-158
GTTS-WQ13311MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-06741086
GTTS-WQ3399MR IVTScrip™ mRNA-Anti-ALB, aALB03(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA aALB03
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW